{
  "docId": "019de072-e9f7-73aa-b63d-f50108da815f",
  "docSlug": "8dc30a1d33d144ab07b1459d0ae0e445",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 43 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 43,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes clinical trial data for DESTINY-Breast04.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-e9f7-73aa-b63d-f50108da815f/21",
  "deckHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f",
  "deckJsonHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f.json",
  "deckAnchorHref": "/decks/019de072-e9f7-73aa-b63d-f50108da815f#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.55,
        "y": 0.295
      },
      "kind": "chart",
      "text": "Efficacy in All Patients (HR+ and HR-): Progression-free Survival (T-DXd 9.9 mo vs TPC 5.1 mo, HR 0.50, P <0.0001); Overall Survival (T-DXd 23.4 mo vs TPC 16.8 mo, HR 0.64, P = 0.001)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72c124c2-109f-40ec-a62f-8c2b2384b82a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "T-DXd = trastuzumab deruxtecan; HER2-low = human epidermal growth factor receptor 2 low; HR+ = hormone-receptor positive; HR- = hormone-receptor negative; mBC = metastatic breast cancer; PFS = progression-free survival; OS = overall survival; TPC = treatment with physician's choice; IHC = immunohistochemistry; CDK4/6i = cyclin-dependent kinase 4/6 inhibitors.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5526fe9d-4b03-4cda-9a21-29a6bb7e27f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.45,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "T-DXd is the first HER2-targeted therapy to demonstrate unprecedented statistically significant and clinically meaningful improvement in PFS and OS versus TPC. Similar magnitude of benefit across all subgroups. Safety is consistent. Establishes HER2-low mBC as a new targetable population.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97b46cda-aaae-4b38-b1ec-14927d9a442e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "DESTINY-Breast04 establishes T-DXd as the new standard of care in HER2-low, HR+/HR- mBC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce8b4024-dd96-4f7e-9c60-b94edd959211",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 21,
      "beatId": "dac5d3e5-2df4-4221-bc5f-29bf435cae43",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Takeaways",
      "beatSlug": null,
      "evidence": "Key takeaways are presented on page 21",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}